1 – 10 of 14
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
Automated quantification of PET/CT skeletal tumor burden in prostate cancer using artificial intelligence : The PET index
- Contribution to journal › Article
-
Mark
Applications of Artificial Intelligence in PSMA PET/CT for Prostate Cancer Imaging
(2023) In Seminars in Nuclear Medicine
- Contribution to journal › Article
- 2022
-
Mark
Freely available artificial intelligence for pelvic lymph node metastases in PSMA PET-CT that performs on par with nuclear medicine physicians
- Contribution to journal › Article
-
Mark
Artificial Intelligence-based Assessment of Prostate Cancer Metastases in PET/CT
(2022) In Lund University, Faculty of Medicine Doctoral Dissertation Series
- Thesis › Doctoral thesis (compilation)
- 2020
-
Mark
Deep learning-based evaluation of normal bone marrow activity in 18F-NaF PET/CT in patients with prostate cancer
- Contribution to journal › Published meeting abstract
- 2019
-
Mark
Deep learning for segmentation of 49 selected bones in CT scans : First step in automated PET/CT-based 3D quantification of skeletal metastases
- Contribution to journal › Article
- 2017
-
Mark
3D skeletal uptake of 18F sodium fluoride in PET/CT images is associated with overall survival in patients with prostate cancer
- Contribution to journal › Article
-
Mark
Association of PET index quantifying skeletal uptake in NaF PET/CT images with overall survival in prostate cancer patients
(2017) American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium In Journal of Clinical Oncology 35(6 Suppl). p.178-178
- Contribution to journal › Published meeting abstract
-
Mark
Automated evaluation of normal uptake in different skeletal parts in 18F-sodium fluoride (NaF) PET/CT using a new convolutional neural network method
- Contribution to conference › Abstract
- 2015
-
Mark
Quantitative imaging by automated bone scan index (BSI) as a response biomarker in standard clinical care of patients with metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide
(2015) American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium In Journal of Clinical Oncology 33(7 Suppl). p.288-288
- Contribution to journal › Published meeting abstract
